Orchid Labs Introduces the Orchid™ Protocol and Tokens to Create an Internet Free from Surveillance and Censorship
Orchid Labs Inc. has unveiled itself publicly today, along with the launch of the private alpha version of its Orchid Network accompanied by a whitepaper. The Orchid protocol is an open-source network intended to end internet surveillance and censorship, while protecting users’ personal data from being harvested by ISPs or other entities. Early in 2018, the blockchain-based Orchid network beta will launch to the public, enabling people across the world to freely communicate, collaborate, and access information.
According to Freedom House, two-thirds of all internet users live in countries where censorship and surveillance limit their ability to access information and communicate. For these individuals, a click or a share can mean imprisonment, or worse. And wherever you live, ISPs and VPNs are profiting from the sale of users’ most sensitive and private information.
Like many other dedicated people around the world, the founders of Orchid Labs are fighting to end these practices and bring an open and liberated internet to everyone in the world. The Orchid protocol is their contribution to this movement for internet freedom—meaning internet that can’t be controlled by corporations or governments and is open and accessible to all. The co-founders share more of their vision and the mission behind the open source technology project that contributes to this cause in the statement they published today.
Founding Team and Leadership
The Orchid founders, an established group of technologists, entrepreneurs, and blockchain experts, have been working in stealth since early 2017 to bring the technology to life. Collectively, the team has extensive expertise in security, networking, blockchain, and open-source software.
- Stephen Bell: Steve started companies in Europe, the U.S., and China before founding Trilogy VC China, where he spent 10 years backing Chinese seed stage startups.
- Brian J. Fox: Brian is an entrepreneur and open-source advocate, the first employee of the Free Software Foundation, and the author of the GNU Bash shell.
- Jay Freeman: Jay is a software engineer and the developer of the Cydia software distribution platform used on millions of jailbroken iOS devices.
- Gustav Simonsson: Gustav is an engineer and developer who helped launch Ethereum in 2015, working with core protocols, clients, and security auditing.
- Dr. Steven Waterhouse: Steven is an experienced investor and entrepreneur, having co-founded RPX Corp, led cryptocurrency projects at Fortress and Pantera Capital, and the Honeycomb product at Sun Microsystems.
An Internet with Encrypted, Decentralized Architecture, Incentivized on the Blockchain
Orchid is building a new, surveillance-free layer on top of the internet. It’s fully decentralized, meaning that rather than traffic being routed through central authorities—like a user’s ISP or VPN—it's instead routed randomly through a network of nodes as bandwidth contributors sign up to share their surplus bandwidth. Users that want to access surveillance-free internet pay the bandwidth contributors in Orchid tokens in a free-market ecosystem. Orchid’s technology also ensures that central authorities can’t monitor traffic or payments, so it’s fully anonymous, for both the bandwidth consumer and the bandwidth contributor.
Advisors and Investors
To help provide counsel, Orchid Labs has enlisted a team of advisors with experience in cryptography and mission-driven projects. Orchid’s advisors include Gavin Wood, Founder & CTO at Parity Technologies; Dr. Dan Boneh, Professor and head of Cryptography at Stanford University’s Computer Science Department; and Alexander Lloyd, human rights advocate and Managing Director of Accelerator Ventures.
To support Orchid Labs and its mission, Orchid has raised a $4.7M seed SAFT (Simple Agreement for Future Tokens) from investors including Sequoia, Andreessen Horowitz, DFJ, PolyChain Capital, Metastable, Blockchain Capital, Crunchfund, Struck Capital, Compound VC, European Investor Richard Muirhead, and several other funds and angel investors.
To learn more about Orchid Labs, read their whitepaper, or sign up for more information, visit orchidprotocol.com.
About Orchid Labs Inc.
Orchid Labs Inc. is an open-source project committed to ending surveillance and censorship on the internet. The Orchid protocol uses an overlay network built upon the existing internet, which is driven by a peer-to-peer tokenized bandwidth exchange, creating a more inclusive, liberated internet. Orchid Labs was founded in 2017 by Stephen Bell, Brian J. Fox, Gustav Simonsson, Dr. Steven Waterhouse, and Jay Freeman. Orchid Labs is headquartered in San Francisco, California.
CMO for Orchid Labs Inc.
Louise Callagy, 415-699-2963
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Manchester United and True Religion Launch Denim Range19.10.2018 20:37 | Tiedote
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10 | Tiedote
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 14:54 | Tiedote
Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr
Tradeshift Announces Q3 2018 Results19.10.2018 14:00 | Tiedote
Tradeshift, the leader in supply chain payments and marketplaces, today announced results from the third quarter of 2018, marking the tenth quarter in a row of successive growth and beating targets. Tradeshift’s third quarter growth stats announced today include: YoY revenue grew 400 percent (trailing 12 months) YoY new bookings grew 284 percent YoY gross merchandise volume (GMV) grew 262 percent New total contract value grew by $47M in Q3 Tradeshift’s customer roster continued strong growth this quarter adding 27 new customers, including Hertz, Shiseido, ECU, and Fortune 500 leaders in retail apparel, agriculture, engineering and construction, hospitality, travel and food delivery. Tradeshift also expanded its app ecosystem by adding a key partnership with Coface, a global credit insurer. Coface has announced a new app solution on the Tradeshift platform offering risk and business information services to help businesses make decisions by ensuring greater financial transparency between
Schlumberger Announces Third-Quarter 2018 Results19.10.2018 14:00 | Tiedote
Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme